1. Changes in quality of life in relation to disease activity in systemic lupus erythematosus: post-hoc analysis of the BLISS-52 Trial. (December 2019) Authors: Jolly, M; Annapureddy, N; Arnaud, L; Devilliers, H Journal: Lupus Issue: Volume 28:Number 14(2019) Page Start: 1628 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
2. Effects of corticosteroids and immunosuppressors on idiopathic inflammatory myopathy related myocarditis evaluated by magnetic resonance imaging. Issue 2 (12th January 2006) Authors: Allanore, Y; Vignaux, O; Arnaud, L; Puéchal, X; Pavy, S; Duboc, D; Legmann, P; Kahan, A Journal: Annals of the rheumatic diseases Issue: Volume 65:Issue 2(2006) Page Start: 249 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
3. FRI0329 Efficacy and safety of infliximab originator in patients with takayasu arteritis within the RTU (temporary recommendation of use) in france. (15th June 2017) Authors: Kleinmann, J-F; Arnaud, L; Sauleau, E; Gouyette, N; Tajima, R; Sibilia, J Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 611 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
4. FRI0626 Analysis of correlation and causes for discrepancy between quantitative and semi-quantitative doppler scores in synovitis in rheumatoid arthritis. (15th June 2017) Authors: Rezaei, H; Klint, E af; Hammer, HB; Terslev, L; D'Agostino, M-A; Kisten, Y; Arnaud, L Journal: Annals of the rheumatic diseases Issue: Volume 76(2017)Supplement 2 Page Start: 726 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
5. GRP-096 Improving Safety of High Risk Medications in a Psychiatric Hospital. (12th March 2013) Authors: Costes, J; Roux-Laplagne, A; Quillard, B; Malard-Gasnier, N; Arnaud, L; Schadler, L; Lombertie, ER Journal: European journal of hospital pharmacy Issue: Volume 20(2013)Supplement 1 Page Start: A35 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
6. Relationship between glucocorticoid dose and adverse events in systemic lupus erythematosus: data from a randomized clinical trial. (4th March 2018) Authors: Emamikia, S; Gentline, C; Chatzidionysiou, K; Arnaud, L; van Vollenhoven, R Journal: Scandinavian journal of rheumatology Issue: Volume 47:Number 2(2018) Page Start: 131 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗
7. Serum soluble tumour necrosis factor receptor-2 (sTNFR2) as a biomarker of kidney tissue damage and long-term renal outcome in lupus nephritis. (4th July 2017) Authors: Parodis, I; Ding, H; Zickert, A; Arnaud, L; Larsson, A; Svenungsson, E; Mohan, C; Gunnarsson, I Journal: Scandinavian journal of rheumatology Issue: Volume 46:Number 4(2017) Page Start: 263 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗